GSK wins approval of antibiotic gepotidacin for urinary tract infections

Wirestock/iStock Editorial via Getty Images The U.S. FDA has approved GSK's ( NYSE: GSK ) Blujepa (gepotidacin), a topoisomerase inhibitor antibiotic for uncomplicated urinary tract infections.

The indication is for females 12 years and older weighing at least 40kg. The recommended dosage is 1,500 mg (two 750 mg tablets) taken.